tradingkey.logo
搜索

武田制药

TAK
添加自选
17.040USD
+0.220+1.31%
收盘 07-23 16:00美东报价延迟15分钟
53.84B总市值
44.43市盈率 TTM

关于 武田制药 公司

Takeda Pharmaceutical Co Ltd is a Japan-based company mainly engaged in the research and development, manufacture, sale and licensing of pharmaceuticals. The Company focuses on the main business areas of gastrointestinal diseases, rare diseases, plasma derivatives (immune diseases), oncology (cancer), and neuroscience (neuropsychiatric diseases). The Company focuses on three research and development areas: innovative biopharmaceuticals with the focus on gastrointestinal and inflammatory diseases, neuroscience, and oncology, plus plasma derivatives and vaccines. Most of the pharmaceuticals treat rare diseases in the focus disease areas and the plasma derivatives area. The Company operates in Japan, the United States, Europe, and China.

武田制药简介

公司代码TAK
公司名称Takeda Pharmaceutical Co Ltd
上市日期Jun 21, 2085
CEOWeber (Christophe)
员工数量47455
证券类型Depository Receipt
年结日Jun 21
公司地址4F
城市CHUO-KU
上市交易所NASDAQ OMX NASDAQ Basic NYSE
国家Japan
邮编103-8668
电话81332782111
网址https://www.takeda.com/
公司代码TAK
上市日期Jun 21, 2085
CEOWeber (Christophe)

武田制药公司高管

名称
名称/职务
职务
持股
持股变动
Dr. Steven H. (Steve) Gillis, Ph.D.
Dr. Steven H. (Steve) Gillis, Ph.D.
Independent Director
Independent Director
15.86K
--
Ms. Kimberly A. Reed
Ms. Kimberly A. Reed
Independent Director
Independent Director
8.97K
--
Mr. Michel Orsinger
Mr. Michel Orsinger
Independent Director
Independent Director
7.60K
--
Ms. Emiko Higashi
Ms. Emiko Higashi
Independent Director
Independent Director
7.60K
--
Mr. Jean-Luc Butel
Mr. Jean-Luc Butel
Independent Director
Independent Director
7.60K
--
Dr. John M. Maraganore, Ph.D.
Dr. John M. Maraganore, Ph.D.
Independent Director
Independent Director
7.60K
--
Mr. Christophe Weber
Mr. Christophe Weber
President, Chief Executive Officer, Representative Director
President, Chief Executive Officer, Representative Director
--
--
Dr. Andrew S. Plump, Ph.D.
Dr. Andrew S. Plump, Ph.D.
President of Research & Development, Director
President of Research & Development, Director
--
--
Mr. Tokumasa Takeda
Mr. Tokumasa Takeda
Global Finance Chief Accounting Officer & Corporate Controller
Global Finance Chief Accounting Officer & Corporate Controller
--
--
Mr. Yoshiaki Fujimori
Mr. Yoshiaki Fujimori
Independent Director
Independent Director
--
--
查看更多
名称
名称/职务
职务
持股
持股变动
Dr. Steven H. (Steve) Gillis, Ph.D.
Dr. Steven H. (Steve) Gillis, Ph.D.
Independent Director
Independent Director
15.86K
--
Ms. Kimberly A. Reed
Ms. Kimberly A. Reed
Independent Director
Independent Director
8.97K
--
Mr. Michel Orsinger
Mr. Michel Orsinger
Independent Director
Independent Director
7.60K
--
Ms. Emiko Higashi
Ms. Emiko Higashi
Independent Director
Independent Director
7.60K
--
Mr. Jean-Luc Butel
Mr. Jean-Luc Butel
Independent Director
Independent Director
7.60K
--
Dr. John M. Maraganore, Ph.D.
Dr. John M. Maraganore, Ph.D.
Independent Director
Independent Director
7.60K
--

常见问题

武田制药的前五大股东是谁?

武田制药 的前五大股东如下:Dr. Steven H. (Steve) Gillis, Ph.D.

有多少机构持有武田制药(TAK)的股份?

截至2026Q1,共有637家机构持有武田制药的股份,合计持有的股份价值约为85.31M,占公司总股份的2.70%。与2025Q4相比,机构持股有所增加,增幅为-8142483.00。

哪个业务部门对武田制药的收入贡献最大?

在2026Q1,Gastrointestinal diseases业务部门对武田制药的收入贡献最大,创收385.81B,占总收入的32.37%。
tradingkey.logo
风险提示:我们的网站和移动应用程序仅提供关于某些投资产品的一般信息。Finsights 不提供财务建议或对任何投资产品的推荐,且提供此类信息不应被解释为 Finsights 提供财务建议或推荐。
投资产品存在重大投资风险,包括可能损失投资的本金,且可能并不适合所有人。投资产品的过去表现并不代表其未来表现。
Finsights 可能允许第三方广告商或关联公司在我们的网站或移动应用程序的任何部分放置或投放广告,并可能根据您与广告的互动情况获得报酬。
© 版权所有: FINSIGHTS MEDIA PTE. LTD. 版权所有